MAIA Biotechnology, Inc.
MAIA- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001878313
In the last 90 days, MAIA Biotechnology, Inc. insiders filed 7 open-market purchases and 0 sales; 43 institutions reported holding it in 13F filings for Q3 2026, worth $14.2M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 10, 2026, 1:20 AM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K |
| Reported | – | – | – | Mar 24, 2023 |
| Revenue | – | $0 | $0 | $0 |
| Operating expenses | $24.3M | $17.0M | $20.2M | $16.2M |
| Research and development | $453.7K | $10.0M | $11.1M | $8.93M |
| Selling, general and administrative | $9.72M | $6.95M | $9.07M | $6.14M |
| Operating income | -$24.3M | -$17.0M | -$20.2M | -$16.2M |
| Interest expense | – | $57 | $6.86K | $6.97K |
| Income tax | $2.00K | – | – | – |
| Net income | -$22.4M | -$23.3M | -$19.8M | -$15.8M |
| EPS, basic | $-0.70 | $-1.05 | $-1.49 | $-1.75 |
| EPS, diluted | $-0.70 | $-1.05 | $-1.49 | $-1.75 |
| Weighted shares, basic | 32.1M | 22.2M | 13.3M | 9.28M |
| Weighted shares, diluted | 32.1M | 22.2M | 13.3M | 9.28M |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K |
| Reported | – | – | – | Mar 24, 2023 |
| Cash and equivalents | $0 | $0 | $0 | $0 |
| Total current assets | $9.70M | $10.2M | $7.56M | $11.8M |
| Total assets | $9.70M | $10.2M | $7.57M | $12.0M |
| Accounts payable | $2.04M | $1.51M | $1.64M | $1.17M |
| Total current liabilities | $5.84M | $3.83M | $4.94M | $3.27M |
| Total liabilities | $7.33M | $6.52M | $7.09M | $3.51M |
| Shareholders' equity | $2.38M | $3.63M | $477.5K | $8.51M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K |
| Reported | – | – | – | Mar 24, 2023 |
| Operating cash flow | -$18.8M | -$15.7M | -$13.1M | -$11.7M |
| Stock-based compensation | $2.63M | $1.91M | $3.09M | $2.32M |
| Financing cash flow | $17.9M | $18.2M | $9.27M | $12.0M |
| Net change in cash | – | $2.45M | -$3.80M | $376.6K |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 9, 2026 | 61.8M | +66.7% | SEC |
| Aug 10, 2026 | 60.8M | +84.4% | SEC |
| May 11, 2026 | 60.8M | +100.6% | SEC |
| Mar 23, 2026 | 60.7M | +105.1% | SEC |
| Nov 7, 2025 | 37.0M | +46.2% | SEC |
| Aug 11, 2025 | 33.0M | +38.0% | SEC |
| May 9, 2025 | 30.3M | +38.8% | SEC |
| Mar 21, 2025 | 29.6M | +47.9% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.